Prescription Law of New Coronavirus Pneumonia in Different Stages

Lu-hua XU; Yan-rong LI; Dan-ru ZHENG; Zong-fang SHAO; Si-qi WEN; Feng-xia LIN; Zi-cong ZENG; Yin-zhi SONG

doi:10.13422/j.cnki.syfjx.20201211

您当前的位置：

首页 >

文章列表页 >

Prescription Law of New Coronavirus Pneumonia in Different Stages

Topic on Epidemic Resistance | 更新时间：2020-08-11

- Prescription Law of New Coronavirus Pneumonia in Different Stages
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 13, Pages: 8-16(2020)
- 作者机构：
  
  广州中医药大学附属宝安中医院，深圳市宝安中医院（集团），广东深圳 518133
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201211
  CLC： R285;R289;R22;R2-031
- Published Online：25 February 2020，
  
  Published：05 July 2020
- 稿件说明：
移动端阅览
许禄华,李彦荣,郑丹如等.探讨新型冠状病毒肺炎不同阶段的处方用药规律[J].中国实验方剂学杂志,2020,26(13):8-16.

XU Lu-hua,LI Yan-rong,ZHENG Dan-ru,et al.Prescription Law of New Coronavirus Pneumonia in Different Stages[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):8-16.
许禄华,李彦荣,郑丹如等.探讨新型冠状病毒肺炎不同阶段的处方用药规律[J].中国实验方剂学杂志,2020,26(13):8-16. DOI： 10.13422/j.cnki.syfjx.20201211.

XU Lu-hua,LI Yan-rong,ZHENG Dan-ru,et al.Prescription Law of New Coronavirus Pneumonia in Different Stages[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(13):8-16. DOI： 10.13422/j.cnki.syfjx.20201211.

摘要

目的

基于“因时制宜”，探讨新型冠状病毒肺炎不同阶段的中医药防治规律，尤其是其中的处方用药规律。

方法

检索并整理2020年2月17日前（含）国家及各省市政府以及各专家制定和发表的新型冠状病毒肺炎指南及建议，按照预防期、临床观察期、临床前期、临床中期、临床后期和恢复期分期录入，对处方中药及其功效、成方和中成药进行频数分析，再对处方中药进行因子分析和聚类分析以获取合理药物组合。

结果

共纳入来自24个官方和24个专家的172条中药处方建议，50个成方建议和31个中成药建议，涉及147个中药，44个方剂和16个中成药；中药处方方面，无论是药物类别选择还是具体药物选择，不同阶段的用药规律均不相同；成方和成药方面，观察期可予藿香正气胶囊、疏风解毒胶囊、连花清瘟胶囊、金花清感胶囊，中期可予宣白承气汤加减，后期可辨证予安宫牛黄丸、苏合香丸或紫雪丹；另外，清肺排毒汤在各时期均可使用。

结论

新型冠状病毒肺炎各阶段用药规律各有特色，临床需随疾病进展，及时变更处方。

Abstract

Objective

To study the clinical medication regulation for the prevention and treatment of new coronavirus pneumonia with traditional Chinese medicine（TCM），especially prescriptions，on the basis of "treatment in accordance with seasonal conditions".

Method

The guidelines and suggestions on novel coronavirus pneumonia formulated and published by national，provincial and municipal governments and experts before February 17，2020

were retrieved and summarized. Data was recorded in stages according to "prevention period，clinical observation period，pre-clinical period，middle clinical period，late clinical period and recovery period". The frequency analysis of TCM and its efficacy，prescription and proprietary Chinese medicine was carried out，and then the factor analysis and cluster analysis of TCM were carried out to obtain rational drug combinations.

Result

Totally 172 suggestions on combined structure of drugs，50 suggestions on prescriptions and 31 suggestions on proprietary Chinese medicine were involved in the study，and provided by 24 official agencies and 24 medical experts， 147 kinds of herbs，44 prescriptions and 16 proprietary Chinese medicines were collected. No matter for the drug category or for the specific drug selection，the law of drug use in different stages was not the same. Huoxiang Zhengqi capsule，Shufeng Jiedu capsule，Lianhua Qingwen capsule and Jinhua Qinggan capsule can be used in the observation period. Xuanbai Chengqitang can be used in the middle of the disease. Angong Niuhuangwan，Suhexiangwan or Zixuedan

and Angong Niuhuangwan can be selected in the middle of the disease. And Qingfei Paidu decoction can be used in all stages of the disease.

Conclusion

Doctors need to adjust their prescriptions along with the progress of the disease，because the law of medication in each stage of the new coronavirus pneumonia is different.

关键词

Keywords

references

Statement on the second meeting of the International Health Regulations (2005 ) Emergency Committee regarding the outbreak of novel coronavirus (2019 -nCoV) [EB/OL]. https://www.who.int/news-room/detail/30-01-2020-statement-on-the-secondmeeting-of-the-international-health-regulations- (2005) -emergency-committee-regarding-the-outbreak-of-novel-coronavirus- (2019-ncov） https://www.who.int/news-room/detail/30-01-2020-statement-on-the-secondmeeting-of-the-international-health-regulations- (2005) -emergency-committee-regarding-the-outbreak-of-novel-coronavirus- (2019-ncov） , 2020-01-30 / 2020-02-08 .

国家卫生健康委员会 . 截至 2 月 20 日 24 时新型冠状病毒肺炎疫情最新情况 [EB/OL]. http://www.nhc.gov.cn/xcs/yqfkdt/202002/ac1e98495cb04d36b0d0a4e 1e7fab545.shtml http://www.nhc.gov.cn/xcs/yqfkdt/202002/ac1e98495cb04d36b0d0a4e 1e7fab545.shtml ， 2020-02-21 / 2020-02-21 .

于明坤，柴倩云，梁昌昊，等 . 新型冠状病毒肺炎中医预防及诊疗方案汇总分析 [J]. 中医杂志， 2020 ， doi： 11.2166.r.20200211.0848.002 http://dx.doi.org/11.2166.r.20200211.0848.002 .

杨道文，李得民，晁恩祥，等 . 关于新型冠状病毒肺炎的中医病因病机思考 [J]. 中医杂志， 2020 ， doi： 11.2166.R.20200217.0906.002 http://dx.doi.org/11.2166.R.20200217.0906.002 .

国家药典委员会 . 中华人民共和国药典：一部 [M]. 北京 : 中国医药科技出版社， 2015 ．

于潼，杨文涛，黄雨琳，等 . 黄芪多糖和灭活H9N2亚型禽流感病毒对C57BL/6小鼠外周血T、B淋巴细胞影响的研究 [J]. 黑龙江畜牧兽医， 2020 ， 591 ( 3 ): 12 - 16 .

LIU D ， XU J ， QIAN G , et al . Selenizing astragalus polysaccharide attenuates PCV2 replication promotion caused by oxidative stress through autophagy inhibition via PI3K/AKT activation [J]. Int J Biol Macromol ， 2018 ， 108 : 350 - 359 .

XUE H ， GAN F ， ZHANG Z ， et al . Astragalus polysaccharides inhibits PCV2 replication by inhibiting oxidative stress and blocking NF- κ B pathway [J]. Int J Biol Macromol ， 2015 ， 81 : 22 - 30 .

熊继柏 . 国医大师熊继柏详细解读湖南省新冠肺炎中医药诊疗方案 [EB/OL]. http://www.hnzyfy.com/news/html/?11947.html http://www.hnzyfy.com/news/html/?11947.html ， 2020-02-05 / 2020-02-21 .

国家卫生健康委办公厅，国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案（试行第六版）的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml , 2020-02-18 / 2020-02-19 .

薛伯寿，姚魁武，薛燕星 . 清肺排毒汤快速有效治疗新型冠状病毒肺炎的中医理论分析 [J]. 中医杂志， 2020 , doi: 11.2166.R.20200216.2004.002 http://dx.doi.org/11.2166.R.20200216.2004.002 .

国家卫生健康委员会，国家中医药管理局 . 关于推荐在中西医结合救治新型冠状病毒感染的肺炎中使用“清肺排毒汤”的通知 [EB/OL]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html , 2020-02-06 / 2020-02-07 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Textual Research on Key Information and Modern Clinical Application of Classical Famous Formula Liumotang

Key Techniques and Methodological Considerations for Formation of Traditional Chinese Medicine Syndrome Classification Standards

Textual Research on Key Information of Classic Prescription Zhuye Shigaotang

Analysis of Ancient Literature and Modern Clinical Application of Tuoli Xiaodusan

Research on Key Information of Classic Famous Prescription Huangqitang and Its Modern Clinical Application

Related Author

ZHANG Xinyu

LI Chong

HU Yixuan

LIANG Luming

ZHAO Ye

LU Xiaoting

WANG Yu

ZHAO Guozhen

Related Institution

Pingyin People's Hospital

State Key Laboratory for Innovation and Transformation of Luobing Theory，Key Laboratory of Cardiovascular Remodeling and Function Research，Chinese Ministry of Education， Chinese National Health Commission and Chinese Academy of Medical Sciences， Qilu Hospital of Shandong University

College of Traditional Chinese Medicine（TCM），Shandong University of TCM

College of TCM，Hubei University of Chinese Medicine

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰